Get started
Author

Ismail Kasujee

Observed names: I Kasujee, I. Kasujee
Institution: Almirall (Spain)
OpenAlex ID: A5083547509
Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
2018 · Andrea Matucci, Alessandra Vultaggio, et al. · Respiratory Research · 202
PDF
Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety
2017 · Adel H. Mansur, Sapna Srivastava, et al. · Respiratory Medicine · 78
PDF
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
2021 · Deepak MW Balak, Stefano Piaserico, et al. · Psoriasis Targets and Therapy · 52
PDF
Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas
2025 · Arnau Domenech, Ismail Kasujee, et al. · Advances in Therapy · 42
PDF
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1‐antihistamine treatment: results of the phase IV open‐label SUNRISE study
2018 · F. Bérard, M.C. Ferrier Le Bouedec, et al. · British Journal of Dermatology · 36
Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma
2018 · Paraskevi Katsaounou, Mikaela Odemyr, et al. · ERJ Open Research · 35
PDF
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice
2023 · Antonio Costanzo, Mar Llamas‐Velasco, et al. · Journal of the European Academy of Dermatology and Venereology · 32
PDF
Implementing well‐being in the management of psoriasis: An expert recommendation
2023 · Rachel Sommer, Ulrich Mrowietz, et al. · Journal of the European Academy of Dermatology and Venereology · 26
PDF
A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
2022 · Gabrielle Becher, Sophia Conner, et al. · Dermatology and Therapy · 25
PDF
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)
2023 · Matthias Augustin, Rachel Sommer, et al. · BMJ Open · 21
PDF
Characterization of patients with atopic dermatitis based on flare patterns and severity of disease: A Danish population‐based study
2024 · Mia‐Louise Nielsen, Lea K. Nymand, et al. · Journal of the European Academy of Dermatology and Venereology · 10
Predictors of Flares and Disease Severity in Patients With Atopic Dermatitis Using Machine Learning
2025 · Mia-Louise Nielsen, Lea K. Nymand, et al. · JAMA Dermatology · 8
Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel
2023 · Brian Berman, April Armstrong, et al. · JAAD International · 8
PDF
Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)
2023 · Todd Schlesinger, Leon Kircik, et al. · SKIN The Journal of Cutaneous Medicine · 6
PDF
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
2025 · Matthias Augustin, Anthony Bewley, et al. · BMJ Open · 5
Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies
2023 · Julie C. Harper, April Armstrong, et al. · Journal of the American Academy of Dermatology · 4
PDF
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
2025 · Ulrich Mrowietz, Rachel Sommer, et al. · Psoriasis Targets and Therapy · 3
PDF
An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis
2022 · Neal Bhatia, April W Armstrong, et al. · SKIN The Journal of Cutaneous Medicine · 3
PDF
Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study
2025 · Andreas Pinter, Jose Luis López Estebaranz, et al. · JEADV Clinical Practice · 2
PDF
Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2
2022 · Igor Dykukha, Andreu Schoenenberger, et al. · Dermatology · 2
Living with severe asthma year 2016
2017 · Paraskevi Katsaounou, Lorena Garcia Conde, et al. · European Respiratory Journal · 2
Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres
2011 · Mark Britton, Timothy Howes, et al. · European Respiratory Journal · 2
Psychological impact on flare patterns and severity of atopic dermatitis
2024 · Mia‐Louise Nielsen, Lea K. Nymand, et al. · Journal of the European Academy of Dermatology and Venereology · 1
52742 Real-world patient/clinician-reported outcomes of tirbanibulin for actinic keratosis: indirect comparison between KLIR and PROAK studies
2024 · Todd Schlesinger, Ismail Kasujee, et al. · Journal of the American Academy of Dermatology · 1
54052 Safety of sarecycline for treatment of acne vulgaris (AV): Real-world results from the PROSES study
2024 · Emmy Graber, Hilary Baldwin, et al. · Journal of the American Academy of Dermatology · 1
Works count: 82
Citation count: 621
H-index: 10
I10-index: 11
Year
Topic
Type